Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 ...

Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently ...

EMERYVILLE, Calif. (AP) — EMERYVILLE, Calif. (AP) — XOMA Royalty Corporation (XOMA) on Wednesday reported second-quarter net income of $9.2 million. On a per-share basis, the Emeryville, ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...

Xoma Royalty has agreed to acquire Lava Therapeutics.

Xoma Royalty has agreed to acquire HilleVax. Emeryville, Calif.-based Xoma plans to begin a tender offer for the Boston vaccine developer by Aug. 18, the biotechnology-royalty aggregator said Monday.

Detailed price information for Xoma Royalty Corporation (XOMA-Q) from The Globe and Mail including charting and trades.

LAVA Therapeutics (LVTX) stock gains as XOMA Royalty (XOMA) agrees to acquire the company for up to $1.24/share plus contingent value rights. Read more here.

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) announced today ...

In a separate transaction, XOMA Royalty will acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, plus a CVR representing the right to receive 75% of net proceeds related to LAVA’s ...

XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA ...